drug
deferasirox ODT
Marketedupdated 3mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
Trials studying deferasirox ODT
- phase2Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
- phase2Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
- phase2Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
- phase2Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
- phase4Pilot Study for Patients With Poor Response to Deferasirox
- phase2The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that